Our data categorize the activation of the WP by molecular subtypes of BC, and associates MMP7, one of the target genes of the WP to PTEN loss, the most common first somatic event associated with basal-like subtype suggesting that the WP pathway can provide attractive pharmacological targets for TNBC. This evidence concerns the gene PTEN and breast cancer.